FDA Approves Less Frequent Lebrikizumab Dosing - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Less Frequent Lebrikizumab Dosing

Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis.

  • By

  • Kathryn Wighton

  • June 10, 2026

  • 2 min

Share

Objective:

To inform about the FDA approval of an every-8-week maintenance dosing regimen for lebrikizumab in treating moderate-to-severe atopic dermatitis.

Approach:
    Key Findings:
    • No new safety signals were identified in the 32-week ADjoin every-8-week extension.
    • No patients discontinued treatment due to adverse events through 32 weeks.
    • Common adverse reactions included conjunctivitis, injection-site reactions, and herpes zoster.
    Interpretation:

    Lebrikizumab is a monoclonal antibody targeting interleukin-13, approved for patients whose disease is not adequately controlled with topical therapies.

    Limitations:
    • The safety profile is based on data from the ADjoin trial and may not encompass all patient populations.
    Conclusion:

    The option for every-8-week maintenance dosing represents a significant development for patients with moderate-to-severe atopic dermatitis.

    Sources:

Original Source(s)

FDA Approves Less Frequent Lebrikizumab Dosing

  • by Kathryn Wighton

  • June 10, 2026

Related Content

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

CDC: Measles cases surpass 4,000 in 2026

CDC data show that 96% of cases are outbreak-associated, with adults accounting for 40% of cases, up from 29% in 2025.